Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1999-12-14
pubmed:abstractText
1 Guanethidine is commonly used as a drug to investigate adrenergic neurotransmission and, in combination with atropine, to realize non-adrenergic non-cholinergic (NANC) conditions. Previous studies suggested a nicotinic acetylcholine receptor blocking effect of guanethidine. Therefore, we investigated the effect of increasing concentrations of guanethidine (0.1-100 microM) on nicotine-induced relaxations of longitudinal muscle strips of rat gastric fundus. 2 In the presence of 1 microM atropine and 3 microM guanethidine, nicotine (30 microM) induces a fast and sustained relaxation which is partly inhibited by the nitric oxide synthase inhibitors Nomega-nitro-L-arginine (L-NOARG) and Nomega-nitro-L-arginine methyl ester (L-NAME) (both 30 and 100 microM). One microM tetrodotoxin (TTX) completely blocks this nicotine-induced relaxation. 3 High concentrations of guanethidine (> or =10 microM), but not adrenoceptor blockade by the alpha-adrenoceptor antagonist phentolamine in combination with the beta-adrenoceptor antagonist nadolol (both 3 microM), inhibit the nicotine-induced relaxation. 4 Guanethidine (0.1-100 microM) has no effect on relaxations induced by electrical field stimulation (EFS; 1-8 Hz), nitric oxide (NO; 0.01-1 microM), vasoactive intestinal polypeptide (VIP; 0.1-10 nM) or isoprenaline (1-10 nM). 5 We conclude that high concentrations of guanethidine (> or =10 microM) block nicotine-induced NANC relaxations of longitudinal muscle strips of the rat gastric fundus most likely at the level of the nicotinic acetylcholine receptor.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-14269604, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-1463368, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-1652335, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-1671594, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-1964906, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-3260776, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-3524491, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-7602539, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-7678206, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-8339469, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-8387048, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-8879538, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556924-9249245
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
128
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
903-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Nicotinic acetylcholine receptor blocking effect of guanethidine in the rat gastric fundus.
pubmed:affiliation
Division of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.
pubmed:publicationType
Journal Article, In Vitro